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Abstract
Long‐term use of benzodiazepines or benzodiazepine receptor agonists is widespread,
although guidelines recommend short‐term use. Only few controlled studies have
characterized the effect of discontinuation of their chronic use on sleep and quality of
life. We studied perceived sleep and quality of life in 92 older (age 55‐91 years) out-
patients with primary insomnia before and after withdrawal from long‐term use of
zopiclone, zolpidem or temazepam (BZDA). BZDA was withdrawn during 1 month,
during which the participants received psychosocial support and blindly melatonin or
placebo. A questionnaire was used to study perceived sleep and quality of life before
withdrawal, and 1 month and 6 months later. 89 participants completed the 6‐month
follow‐up. As melatonin did not improve withdrawal, all participants were pooled and
then separated based solely on the withdrawal results at 6 months (34 Withdrawers.
55 Nonwithdrawers) for this secondary analysis. At 6 months, the Withdrawers had
significantly (P < 0.05) shorter sleep‐onset latency and less difficulty in initiating
sleep than at baseline and when compared to Nonwithdrawers. Compared to baseline,
both Withdrawers and Nonwithdrawers had at 6 months significantly (P < 0.05) less
fatigue during the morning and daytime. Stress was alleviated more in Withdrawers
than in Nonwithdrawers (P < 0.05). Satisfaction with life and expected health 1 year
later improved (P < 0.05) inWithdrawers. In conclusion, sleep disturbances, daytime
fatigue and impaired quality of life may resolve within 6 months of BZDA with-
drawal. These results encourage withdrawal from chronic use of benzodiazepine‐type
hypnotics, particularly in older subjects.
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1 | INTRODUCTION
Insomnia is a frequent problem among older individuals.
Benzodiazepines and related drugs (here BZDA) are
recommended for short‐term treatment of insomnia only,
but their long‐term use is widespread.1-4 Chronic BZDA
use in older adults is associated with an increased risk of
adverse outcome such as balance difficulties, falling, cogni-
tive impairment, dementia and increased mortality.5-13
Various strategies have been applied to improve the qual-
ity of hypnotic prescription and to withdraw BZDA hyp-
notics from their chronic users.14-19 In Finland in 2009, that
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is, when this study was started, sales of BZDA hypnotics
were 51.4 defined daily doses (DDD)/1000 inhabitants, and
zopiclone and zolpidem together with temazepam accounted
for over 90% of the total hypnotic sales.20
Rebound symptoms, such as exacerbation of insomnia
and anxiety, are usual after discontinuation of prolonged
BZDA use. However, interindividual variation in sensitivity
to rebound symptoms is large and may depend, for exam-
ple, on pharmacokinetic properties and doses of the
BZDAs used, duration of use, as well as on personality
and concomitant diseases. Psychotherapeutic interventions
and gradual BZDA dose reduction can alleviate rebound
symptoms and improve withdrawal success.15-19
Only very few controlled studies have involved the
effect of withdrawal from the long‐term use of BZDA hyp-
notics on sleep and the quality of life in older people.21,22
Our purpose was to investigate, as a part of our Satauni‐
BZDA withdrawal trial,23 how older chronic BZDA users
perceive their sleep and their quality of life before and after
successful withdrawal. Accordingly, we compared the sub-
jective sleep, freshness, and quality‐of‐life parameters at
months 1 and 6 after start of dose-tapering to their baseline
value within those participants who totally withdrew from
BZDAs, and within those who continued their BZDA use
as hypnotics. Furthermore, we compared these parameters
between the Withdrawer‐ and Nonwithdrawers groups.
2 | MATERIALS AND METHODS
2.1 | Study design
The details of study design, the participants and the BZDA
withdrawal results of our Satauni study have appeared ear-
lier,23 but no results on the effects of the BZDA withdrawal
on the sleep and quality of life have been reported previ-
ously. In short, we performed during the years 2009‐2010 a
randomized, double‐blind, placebo‐controlled, parallel‐group
study on the efficacy of daily melatonin (2 mg) in BZDA
withdrawal during a 1‐month period and a double‐blind 5‐
month follow‐up (Figure 1). Randomization codes were
decoded only at the end of follow‐up. As melatonin did not
improve withdrawal, the groups were pooled and then sepa-
rated solely based on the BZDA withdrawal results at
6 months (34 Withdrawers vs 55 Nonwithdrawers) for this
secondary analysis. The study protocol was approved by the
Ethics Committee of Satakunta Hospital District (2§/7/2008)
and by the National Agency for Medicines of Finland (218/
2008; EudraCT 2008–0006795‐30).
2.2 | Study population
Participants were primary healthcare outpatients who vol-
untarily entered our BZDA withdrawal study. A physician
met the potential participants for screening and recruitment.
Written informed consent came from each participant
before the study began.
The participants, men and women, had to be at least
55 years old and be chronic users of zopiclone, zolpidem or
temazepam as hypnotics, defined as 1 month or longer regu-
lar night‐time use. The hypnotics must have been prescribed
according to DSM‐IV criteria for primary insomnia. The key
exclusion criteria were concurrent use of other benzodi-
azepines or antipsychotic or anti‐epileptic medications, a his-
tory of alcohol or drug abuse, severe anxiety disorder, or
other severe psychiatric or neurological diseases, cancer or
smoking of more than 10 cigarettes daily. Of the 92 initially
recruited participants, two dropped out during the BZDA
withdrawal period and one during the follow‐up. We report
here the sleep and quality‐of‐life data of those 89 individuals
who were followed up for 6 months (Figure 1).
2.3 | Interventions
At baseline, a physician provided psychosocial support and
individual sleep‐hygiene counselling, including discussions
with participants about regular sleep rhythm and the influ-
ence of the following on sleep: normal changes in sleep
patterns related to ageing, the situation regarding the bed-
room and bed, exercise, diet and alcohol use, coffee and
stimulants prior to sleeping, deep and calm breathing, and
psychological and physical relaxation in bed. If they were
not asleep within 15 min., they were counselled to rise and
do something relaxing.23
The physician performed a clinical examination and,
in agreement with the participant, determined an individ-
ual withdrawal schedule which aimed to complete dis-
continuation of BZDA use within 1 month. Most often,
the recommended reduction from the initial BZDA daily
dose was 50% per week. The initial dose reduction was
25% per week among those eleven participants with the
highest BZDA dose, that is, more than twice the age‐
related defined daily dose (DDD), and among some other
participants who were afraid of withdrawal symptoms.
Length of BZDA use was not used as a criterion for
dose‐tapering rate; only two of the participants had used
BZDA less than for 1 year. The physician informed each
participant as to possible withdrawal symptoms, espe-
cially rebound insomnia. The psychosocial support was
further continued by a nurse who provided supportive
visits once a week during the withdrawal period and was
available by phone.
2.4 | Measurements and data collection
Interviews completed by questionnaire took place at
baseline, after the 1‐month withdrawal period, and
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6 months after withdrawal initiation (Figure 1). At base-
line, we collected socio‐demographic data and data on
health and disease, including mood measurement by the
Geriatric Depression Scale 15 (GDS‐15).24 We scruti-
nized BZDA use by interview at baseline and at months
1 and 6. In addition, we measured concentrations of
zopiclone, zolpidem, temazepam, diazepam, desmethyl-
diazepam and oxazepam in plasma samples drawn at
baseline and at month 1.23
The nurse performed baseline measurements. Subse-
quent contacts with the nurse consisted of interviews, mea-
surements and psychosocial support (at weeks 1, 2, 3 and
4 from baseline). Participants also had the option during
the withdrawal period for psychosocial support sessions
with the physician. The nurse's follow‐up re‐assessments
occurred at months 2 and 6 after withdrawal initiation, and
the physician's follow‐up examination was at month 6 after
withdrawal initiation (Figure 1).
The structured questionnaire included questions derived
mainly from the Basic Nordic Sleep Questionnaire
(BNSQ), which is a valid tool as a quantitated measure of
subjective sleep complaints.25 These questions assessed the
insomnia‐related symptoms, such as length of sleep‐onset
latency in the evening, frequency of difficulty in initiating
sleep, frequency of awakenings during night and use of
additional medicine (hypnotic) at any nightly awakening
(Table 2). Questions regarding following‐day freshness
mapped too‐early‐morning awakenings, fatigue in the
morning and during daytime, sleepiness during daytime
and compulsive sleepiness on weekdays (Table 2). The
quality‐of‐life questions assessed the life quality in general,
and self‐perceived stress, satisfaction with life, self‐reported
One-month withdrawal period, melatonin/placebo,
psychosocial supportive visits with a nurse (weeks 1, 2, 3, 4)
n =36n =30
Assessed for eligibility (n = 211) 
-Not meeting inclusion criteria (n = 83)




Follow-up, double-blind up to 6 mo
Physician’s and nurse’s visit (n = 69)
-measurements, questionnaire
Nurse’s visit = A participant’s visit at the Health Centre for individual psychosocial support and follow-up 
measurements performed by the nurse. BZDA = benzodiazepine agonist
Questionnaire, measurements and counselling (n = 92) 
-baseline measurements by a nurse, plasma samples
-sleep hygiene counselling and individual withdrawal plan by a physician
Baseline
No BZDA in plasma:
Short-term withdrawers (n = 70) 
-measurements, questionnaire
Drop outs (n = 2) 
1 mo
Physician’s and nurse’s visit (n =20)
-measurements, questionnaire
BZDA in plasma: 
Short-term nonwithdrawers (n = 20) 
-measurements, questionnaire
Withdrawers at 6 months (n = 34) Irregular users (n = 44) Regular users (n =11)
n =3 n = 4 n = 8 n = 8
Two advertisements in a local newspaper in February and August 2009 
Personnel at local health centers provided enrolment information
Nurse’s visit (n = 69) 
-measurements
Nurse’s visit (n = 20)
-measurements




Withdrawers (n = 34) Nonwithdrawers (n =55)Final groups: 
FIGURE 1 Flow of participants and
formation of the groups Withdrawers and
Nonwithdrawers
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health, and expected health 1 year later (Table 3). Quality
of life was mapped by the visual analogue scale (VAS) at
0 to 100 mm (0 = worst, 100 best). Other questions
included three to six alternative answers. The answers rep-
resented the situation from the 3‐month period before the
beginning of BZDA withdrawal (“baseline”), from the 1‐
month period after beginning of withdrawal (“month 1”),
and from the 3‐month period before the end of the follow‐
up (“month 6”). Because some of the questionnaires had
been fulfilled incompletely, the number of participants (n)
answering to all questions was not 89 at each time‐point.
2.5 | Final study groups and statistical
analyses
At month 6, the physician (RL) and two research nurses
determined the withdrawal status by interview using a struc-
tured questionnaire (26) and by checking carefully the partic-
ipants’ medical and prescription records in the Finnish health
system for potential refills as described earlier (23). All the
89 participants who had completed the 6‐month follow‐up
were assigned into one of the two groups solely based on the
BZDA use at month 6, independent of whether they had been
double‐blindly on melatonin or placebo during the actual 1‐
month withdrawal. The two groups formed were those 34
participants who had completely withdrawn from use of
BZDA at month 6 (Withdrawers) and those 55 participants
who still used a BZDA at month 6 (Nonwithdrawers). Distri-
bution of the melatonin and placebo users during the first
withdrawal month did not differ between the groups
(P = 0.220). Of note, also 44 of the Nonwithdrawers had
reduced their BZDA doses or had been without them for
some time after the withdrawal, but at month 6, they failed to
totally abstain from BZDA.
Categorical variables are described as number of partici-
pants (n), and continuous variables by medians and ranges
or by means and standard deviations (SD). Differences
between the Withdrawers and Nonwithdrawers underwent
testing by Student's t test, the Tukey‐Kramer test, the Wil-
coxon signed‐rank test or by the Mann‐Whitney U test,
when appropriate. Variables measured with ordinal or nomi-
nal scales between the groups were tested by the chi‐square
or Fisher's exact test. The differences in changes between
and within the Withdrawer and Nonwithdrawer groups were
analysed by cumulative logistic regression using generalized
estimating equations with an independent correlation struc-
ture and described as cumulative odds ratios (COR) with
95% confidence intervals (CI). In general, COR ≥ 1 values
for categorical variables suggest improvement in parameter
within the group of Withdrawers and Nonwithdrawers com-
pared to baseline. COR is statistically significant (P < 0.05;
bolded in Tables 2 and 3) when its CI does not include 1.0.
For continuous variables, mean changes within groups are
statistically significant (bolded) when CI does not include
0.0. None of the group × time interactions were significant
(P ≥ 0.05), which suggests that the changes (baseline vs
other time‐points) between the groups were not statistically
different. Continuous variables were calculated by least
squares means with SD. Significant differences between the
Withdrawer‐ and Nonwithdrawer groups are indicated by
asterisk (*) in Tables 2 and 3. Due to multiple comparisons,
P‐values were adjusted by the Dunnett‐Hsu test. P‐values <
0.05 were considered statistically significant. For clarity,
only P‐values, without COR and 95% CI, are given in the
text. The statistical analyses were by SAS version 9.2 and
Enterprise Guide version 4.1 (SAS Institute Inc., Cary, NC,
USA).
3 | RESULTS
3.1 | Patient characteristics
The groups differed significantly only by age (Table 1).
Withdrawers were somewhat younger (median 63 years)
than Nonwithdrawers (median 67 years; P = 0.041). At
baseline, the groups did not differ in number of medica-
tions, in duration of regular sedative hypnotic use or in per-
centage of participants using antidepressants.
3.2 | Sleep and freshness variables
3.2.1 | Sleep‐onset latency
The sleep‐onset latency was similar in both groups at base-
line (Figure 2). At month 6, the latency in the Withdrawers
was shorter than at baseline (P = 0.006) or in the Non‐
withdrawers (P = 0.017). (Tables 2 and 4). In the With-
drawers, the percentage of those participants with the long-
est sleep‐onset latency (>30 minutes) decreased from 52%
at baseline to 24% at month 6 but remained unchanged
(51%) in the Nonwithdrawers (Figure 2).
3.2.2 | Difficulties in initiating sleep
At baseline, most of the participants in both groups every
night had difficulties in initiating sleep (Table 2). At month
6, the Withdrawers had fewer difficulties than at baseline
(P = 0.002) or compared to the Nonwithdrawers
(P = 0.042).
3.2.3 | Nocturnal awakenings
The Nonwithdrawers had at month 6 slightly less nocturnal
awakenings than at baseline. However, no significant differ-
ences emerged in nocturnal awakenings between the With-
drawers and Nonwithdrawers at any time‐point (Tables 2).
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3.2.4 | Additional medicines at nocturnal
awakenings
At baseline, 26% of the Withdrawers and 18% of the
Nonwithdrawers nightly used additional sleep medicines,
but both groups had markedly reduced their use of addi-
tional medicines at month 1 (Figure 3, Table 2). At
month 6, none of the Withdrawers used additional
medicines (P < 0.0001 vs baseline), with a significant
difference in their use between the Withdrawers and
Nonwithdrawers (P = 0.034). The Nonwithdrawers also
used additional medicines at month 6 less often than at
baseline (P = 0.003) (Table 2).
3.2.5 | Early‐morning awakenings
At baseline, most of the participants in both groups suf-
fered from too‐early‐morning awakenings once a week or
more frequently (Table 2). At month 6, compared to base-
line, early‐morning awakenings were significantly less fre-
quent in both groups (P < 0.05).
3.2.6 | Fatigue in mornings and during days
At baseline, many of the participants had in the mornings a
feeling of non‐restorative sleep (Table 2). Compared to
baseline, their morning fatigue and daytime fatigue were
diminished in both groups at month 6 (P < 0.05‐
P < 0.001).
3.2.7 | Compulsive sleepiness on weekdays
At baseline, the Withdrawers group suffered from
compulsive sleepiness on weekdays more than did the
TABLE 1 Characteristics of 89 long‐term hypnotic users at
baseline grouped according to withdrawal results at month 6.
Withdrawers (n = 34) totally discontinued, Nonwithdrawers (n = 55)
continued their sedative hypnotic use
Variable
Withdrawers Nonwithdrawers
PMedian [Range] Median [Range]
Age (y) 63.0 [55‐78] 67.0 [55‐91] 0.041
Body mass index
(kg/m²)
26.4 [18.8‐37.1] 27.3 [21.3‐41.6] 0.440
Doses of alcohol
per week
1.5 [0‐25.5] 0 [0‐13.3] 0.242
Number of
medications
4 [1‐10] 4 [1‐11] 0.983
Regular sedative
hypnotic use (y)
8.0 [0.42‐35] 10.0 [2‐26] 1.000
n (%) n (%)
Women 19 (56) 40 (73) 0.102
Exercise in a week (h) 1.000
Not at all 2 (6) 4 (7)
½‐3 h 31 (91) 49 (89)
>3 h 1 (3) 2 (4)
Smokers 2 (6) 4 (7) 1.000
Living alone 6 (18) 19 (35) 0.085
Antidepressive
medication





2 (6) 7 (13) 0.473
Occupation
Retired 24 (71) 48 (87) 0.062
Daytime work 6 (18) 6 (11)
Shift work 4 (12) 1 (2)
GDS‐15, Geriatric Depression Scale.

















































FIGURE 2 Sleep‐onset latency. Percentage of participants within
groups of Withdrawers (Ws) and Nonwithdrawers (NWs) according
to sleep‐onset latency (>30 minutes, 10‐30 minutes or <10 minutes)
at baseline (0 month), and at 1 month and at 6 months after
beginning of withdrawal from chronic hypnotic use. The participants
were classified as Ws (n = 34) or NWs (n = 55) based on their
withdrawal results at month 6
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Nonwithdrawers. Compared to baseline, compulsive sleepi-
ness was diminished only in the Withdrawers group
(P = 0.043) at month 6 (Table 2).
3.2.8 | Length of sleep time
No significant differences emerged in the length of total
sleep time or sleep during nights between the Withdrawers
TABLE 2 Sleep and freshness parameters at baseline and at month 1 and 6. Withdrawers (Ws; n = 34) had discontinued, but
Nonwithdrawers (NWs; n = 55) continued their hypnotic use at 6 months after start of withdrawal. Data are number of participants and odds
ratios (COR) for categorical variables, and mean values and changes for continuous variables
Parameter and group
At baseline At month 1 vs baseline At month 6 vs baseline
n COR (95% CI) COR (95% CI)
Sleep‐onset latency (min) <10, 10-30, >30
Withdrawers 1, 15, 17 1.2 (0.5, 2.6) 2.9 (1.3, 6.2)*
Nonwithdrawers 3, 24, 28 1.9 (0.97, 3.5) 0.9 (0.5, 1.7)
Difficulties initiating sleep (nights/wk) <1, 1-5, ≥6
Withdrawers 4, 11, 19 2.3 (0.9, 5.8) 5.6 (1.8,17.0)*
Nonwithdrawers 2, 10, 43 6.7 (3.2, 14.1) 8.6 (3.9, 18.8)
Awakenings during night (nights/week) <1, 1-5, ≥6
Withdrawers 2, 8, 24 1.1 (0.5, 2.6) 1.1 (0.6, 2.2)
Nonwithdrawers 3, 10, 42 1.0 (0.6, 1.8) 2.4 (1.2, 5.0)
Additional night medicine (nights/wk) <1, 1-5, ≥6
Withdrawers 23, 2, 9 17 (2, 142) NA*
Nonwithdrawers 37, 8, 10 4.5 (2.0, 9.9) 2.7 (1.4, 5.2)
Too‐early‐morning awakenings/wk <1, 1-5, ≥6
Withdrawers 8, 21, 5 1.0 (0.5, 2.0) 2.7 (1.1, 6.5)
Nonwithdrawers 15, 29, 11 1.6 (0.4, 1.1) 3.8 (2.0, 7.3)
Morning fatigue, sleep didn't refresh;
how often? I never; II < 1; III ≥1/mo
I, II, III
Withdrawers 11, 3, 20 0.5 (0.2, 1.2) 0.2 (0.1, 0.5)
Nonwithdrawers 24, 4, 27 0.6 (0.4, 1.1) 0.4 (0.2, 0.8)
Daytime fatigue (d/week) <1, 1-5, ≥6
Withdrawers 10, 16, 7 1.1 (0.5, 2.4) 3.4 (1.7, 6.8)
Nonwithdrawers 20, 22, 13 1.3 (0.8, 2.1) 1.8 (1.1, 3.2)
Sleepy during d (d/wk) <1, 1-5, ≥6
Withdrawers 16, 13, 5 1.5 (0.7, 3.1) 1.7 (0.9, 3.3)
Nonwithdrawers 34, 14, 7 0.8 (0.5, 1.3) 0.96 (0.5, 1.8)
Compulsive sleepiness (d/wk) <1, 1-5, ≥6*
Withdrawers 26, 8, 0 1.7 (0.6, 4.5) 2.9 (1.04, 7.9)
Nonwithdrawers 51, 3, 1 0.6 (0.2, 1.9) 0.5 (0.2, 1.6)
Total sleep time (h) Mean (SD) Mean (SD) Change (95% CI) Mean (SD) Change (95% CI)
Withdrawers 6.7 (1.1) 6.1 (1.6) −0.6 (−1.1, −0.0) 7.1 (1.2) 0.4 (−0.1, 1.0)
Nonwithdrawers 6.7 (1.2) 6.1 (1.1) −0.5 (−0.9, −0.2) 6.7 (1.2) −0.1 (−0.4, 0.3)
Sleep during nights (h)
Withdrawers 6.4 (0.9) 6.0 (1.7) −0.4 (−1.0, 0.2) 7.0 (1.1) 0.5 (−0.0, 1.1)
Nonwithdrawers 6.5 (1.1) 6.1 (1.2) −0.4 (−0.8, −0.1) 6.6 (1.2) 0.1 (−0.3, 0.4)
COR, Cumulative Odds Ratio compared to baseline within the group; CI, Confidence Interval; SD, standard deviation; COR > 1 suggests improvement in other
sleep and freshness parameters but in morning fatigue COR < 1 means improvement; COR is statistically significant (bolded; P < 0.05) when CI does not include
1.0; NA, COR not available due to zero frequencies, P < 0.0001 (Wilcoxon signed rank test); Mean change from baseline within the group is statistically significant
when CI does not include 0.0; n, number of participants; *Asterisk indicates significant difference between the Ws and NWs groups at the time. Group x time inter-
action effects (= changes from baseline) between groups were not significant (P > 0.05).
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and Nonwithdrawers (Table 2). Compared to baseline, the
total sleep time was at month 1 significantly shorter in both
groups, but sleep during nights was significantly shortened
only in Nonwithdrawers (P = 0.007). At month 6, both the
total and nocturnal sleep times were significantly longer
than at month 1 in both groups.
3.3 | Quality‐of‐life parameters
3.3.1 | Quality of Life (QOL)
The groups did not differ from each other in QOL at any
time‐point as assessed by the visual analogue scale. How-
ever, in the Withdrawers group, QOL was improved at
month 1 (P = 0.013) and at month 6 (P = 0.015) com-
pared to baseline (Table 4), and Nonwithdrawers had an
improved QOL at month 6 (P = 0.003) compared to base-
line (Figure 4).
3.3.2 | Geriatric Depression Scale
Differences in the Geriatric Depression Scale between or
within the groups at any time‐points (Table 3) failed to
reach significance.
3.3.3 | Self‐perceived stress
At month 6, the self‐perceived stress was in the Withdraw-
ers group less than at baseline (P = 0.029) or than in the
Nonwithdrawers group (P = 0.039) (Table 4).
3.3.4 | Satisfaction with life
At month 6, satisfaction with life was improved compared
to baseline only in the Withdrawers group (P = 0.012
(Table 4), but with no significant differences between the
groups at any time‐point (Table 3).
3.3.5 | Self‐reported health
No significant differences in the self‐reported health existed
between the groups at any time (Table 4).
3.3.6 | Expected health 1 year later
This parameter was in the Withdrawers better at month 6
than at baseline (P = 0.003), but it did not differ signifi-
















































FIGURE 3 Additional sleep medicines. Percentage of
participants within groups of Withdrawers (Ws) and Nonwithdrawers
(NWs) according to use of additional sleep medicines at nocturnal
awakenings (on every night, on 1‐5 nights/week, <1 night/week) at
baseline (0 month), and at 1 month and at 6 months after beginning
of withdrawal from chronic hypnotic use. The participants were
classified as Ws (n = 34) or NWs (n = 55) based on their withdrawal





















FIGURE 4 Quality of life, measured using visual analogue scale
(VAS 0‐100 mm; 0 = worst, 100 = best), of Withdrawers (Ws) and
Nonwithdrawers (NWs) at baseline (0 month), and at 1 month and at
6 months after beginning of withdrawal from chronic hypnotic use.
The participants were classified as Ws (n = 34) or NWs (n = 55)
based on their withdrawal results at month 6. For clarity, only mean
values are shown. P‐values refer to statistically significant differences
compared to baseline values (NS, not significant)
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3.4 | Summary of results
Effects of the complete BZDA discontinuation on insom-
nia‐related parameters 6 months after start of the with-
drawal are summarized in Table 4.
4 | DISCUSSION
4.1 | General discussion
Our results indicate that withdrawal from long‐term use
of BZDA hypnotics may markedly improve the sleep
and quality of life of older adults with primary insomnia.
Some of the parameters were improved also in the
Nonwithdrawers, probably because most of them also man-
aged from time to time without BZDAs, or they had
reduced their BZDA dose, or both. All participants had
used zopiclone, zolpidem or temazepam nightly for a long
time until they entered the withdrawal.
Studies on perceived sleep and objective sleep are
known to produce somewhat differing results.27 To investi-
gate prospectively the perceived effects of withdrawal
under natural home conditions, we assessed all participants
thrice using the same structured questionnaire. The ques-
tionnaire assessed the main manifestations of insomnia,
freshness and quality of life.24-28 Thus, our results also
offer some hints as to their time‐course after discontinua-
tion of BZDAs.
TABLE 3 Quality of life parameters at baseline and at month 1 and 6. Withdrawers (Ws; n = 34) had discontinued but Nonwithdrawers
(NWs; n = 55) continued hypnotic use at 6 months after start of withdrawal. Data are mean values and their changes for continuous variables,
and number of participants (n) and odds ratios for categorical variables. Statistically significant differences from baseline within group are
bolded, and difference between groups indicated by asterisk
Parameter and group At baseline
At month 1 vs. baseline At month 6 vs. baseline
Mean (SD) Mean (SD) Change (95% CI) Mean (SD) Change (95% CI)
Quality of life (VAS 0‐100 mm; 0 = worst;100 = best)
Withdrawers (mm) 69.7 (19.7) 77.5 (13.0) 7.8 (1.5, 14.0) 77.4 (19.2) 7.6 (1.4, 13.9)
Nonwithdrawers (mm) 69.3 (14.5) 72.5 (12.5) 3.2 (−0.1, 6.5) 74.3 (12.3) 4.8 (1.5, 8.2)
n COR (95% CI) COR (95% CI)
Depression (GDS‐15)
(scores; 0‐5, no depression = I; 6‐15, depressed = II) I, II
Withdrawers (n) 32, 2 1.0 (0.2, 4.4) 2.1 (0.5, 8.6)
Nonwithdrawers (n) 47, 7 1.2 (0.5, 3.0) 1.5 (0.6, 3.7)
Self‐perceived stress
(mild = I, moderate II, severe = III) I, II, III
Withdrawers (n) 27, 6, 1 8.5 (1.3, 57) 4.0 (1.2, 14)*
Nonwithdrawers (n) 45, 6, 4 1.6 (1.04, 2.5) 1.2 (0.7, 2.0)
Satisfaction with life
(good = I, moderate = II, bad =III) I, II, III
Withdrawers (n) 24, 8, 2 1.9 (0.9, 4.2) 3.1 (1.3, 7.4)
Nonwithdrawers (n) 38, 14, 3 1.6 (0.9, 2.9) 1.7 (0.9, 3.2)
Self‐reported health
(good = I, fair = II, bad =III) I, II, III
Withdrawers (n) 9, 24, 1 1.6 (0.9, 2.8) 2.1 (0.9, 5.2)
Nonwithdrawers (n) 9, 46, 0 1.6 (0.9, 2.8) 2.0 (1.04, 3.9)
Expected health 1 year later
(good = I, fair = II, bad = III) I, II, III
Withdrawers (n) 5, 29, 0 1.8 (0.8, 4.1) 3.6 (1.6, 8.2)
Nonwithdrawers (n) 13, 42, 0 0.9 (0.6, 1.4) 1.2 (0.7, 2.3)
COR, Cumulative Odds Ratio compared to baseline within the group; Change, mean change from baseline; CI, 95% Confidence Interval; SD, Standard deviation;
COR > 1 suggests improvement in parameter compared to baseline; COR is statistically significant (bolded; p < 0.05) when CI does not include 1.0. Change is
significant when CI does not include 0.0; n, number of participants. *The only significant difference between the groups was in Self‐perceived stress at month 6.
Group × time interaction effects (=changes from baseline) were not significant (p > 0.05).
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Rebound insomnia is usual in chronic BZDA users after
discontinuation.29,30 Anxiety, nightmares and concentration
impairments may also occur. As could be expected, many
of our participants reported rebound insomnia lasting a
night or two after each BZDA dose reduction. Accordingly,
the total sleep time remained shortened at the end of the
withdrawal period, 1 month after start of the gradual dose
reductions. The dose‐tapering period in our study was
shorter than that usually recommended.29 It is likely that
sleep physiology was not fully normalized by 1 month.
Self‐perceived stress had, however, already diminished
within 1 month. In Nonwithdrawers, also sleep during
nights was significantly shortened at month 1, which may
have contributed to their poorer withdrawal success. At
month 6 in the Withdrawers group, several of the perceived
sleep parameters had recovered, suggesting improved sleep
physiology and that sleep had become more restorative.
The rate of BZDA dose tapering is a somewhat con-
tentious issue.29 Although some long‐term users may
require withdrawal over years, some chronic users can dis-
continue rapidly with little upset.29 For example, with-
drawal over 2‐3 months but slower if the symptoms
become too severe, or 1‐month of withdrawal for each year
of use, has been recommended (15,18,19,21,29). The
1‐month dose tapering used in our study was relatively short.
However, the participants had used BZDAs as hypnotics,
mainly in therapeutic doses, and the short‐term withdrawal
results were good; about 75% were BZDA‐free after the first
month. This may be explained by intensive psychosocial
support during the withdrawal and patients motivated to par-
ticipate in the study. They had received both written and oral
guidelines about insomnia and its treatment without medici-
nes (23). When the participants were told that withdrawal
symptoms are temporary and would pass, many of them
even accepted being awake for 2 or 3 nights during the
withdrawal period. Most of the participants were satisfied
with the short withdrawal when they were interviewed at
6 months. However, it is possible that many participants
could have benefitted from a longer withdrawal period or
more psychosocial support after the withdrawal to accom-
plish healthier sleep patterns without BZDAs.
In general, our results agree with those of Belleville and
Morin (2008), who reported overall improvement in insom-
nia, anxiety and distress symptoms in 15 chronic hypnotic
users after successful discontinuation of sedative hyp-
notics.21 In the study of Curran et al., in chronic users of
temazepam, nitrazepam and loprazalam, withdrawers had
higher health‐related quality‐of‐life scores compared to
TABLE 4 Summary of results of sleep‐related parameters in elderly outpatients at month 6 after start of withdrawal from zopiclone, zolpidem
and temazepam. These chronic hypnotic users had volunteered in dose tapering during the first study month. At 6 months, the Withdrawers
(n = 34) had totally discontinued but Nonwithdrawers (n = 55) continued hypnotic use
Parameter
Within Withdrawers,
month 6 vs baseline
In Withdrawers vs Nonwithdrawers
at month 6
Perceived sleep and next day freshness
Sleep‐onset latency Shortened, P = 0.006 Shortened, P = 0.017
Difficulties initiating sleep Less, P = 0.002 Less, P = 0.042
Awakenings during night NS NS
Additional sleep medicine during night Less, P = 0.0001 Less, P = 0.034
Total sleep time NS NS
Sleep time during nights NS NS
Too‐early‐morning awakening Less, P = 0.031 NS (P = 0.058)
Morning fatigue, sleep didn′t refresh Less, P = 0.0003 NS
Daytime fatigue Less, P = 0.0007 NS
Sleepy during d NS NS
Compulsive sleepiness on weekdays Less, P = 0.043 NS
Quality of life
Quality of life (VAS) Better, P = 0.015 NS
Self‐perceived stress Less, P = 0.029 Less, P = 0.039
Satisfaction with life Better, P = 0.012 NS
Self‐reported health NS NS
Expected health 1 y later Better, P = 0.003 NS
NS, no significant difference; VAS, Visual analogue scale.
Baseline = before start of withdrawal.
P, difference within withdrawers, or between withdrawers and nonwithdrawers at 6 mo.
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continuers but their sleep ratings did not differ when
assessed 12 and 24 weeks after beginning of the withdrawal
trial.22 In our study, most of the 89 evaluable participants
had been long‐term users of the Z‐drugs (zopiclone, 50 par-
ticipants; zolpidem, 26 participants) and only 13 had used
temazepam before the withdrawal trail. Thus, our results
likely reflect the effects of Z‐drug withdrawal, whereas the
previous follow‐up studies21,22 have included no or very
few chronic users of zopiclone and zolpidem.
We have found previously that muscle strength and bal-
ance of these same Withdrawer participants improved within
some weeks after discontinuation of BZDAs.7 On the other
hand, no significant improvement was evident in their atten-
tional or psychomotor cognitive functioning, not even within
6 months after BZDA withdrawal.9 In some other studies,
minor improvement in cognitive functions occurred during
longer periods after BZDA discontinuation.22,30
4.2 | Clinical implications
Clinical relevance of the present findings seems obvious
provided that BZDA withdrawal can be implemented into
primary health care. In our study, the percentage of suc-
cessful withdrawers was 37% (34/92) of the long‐term
BZDA users, who voluntarily participated in this study. As
the withdrawal improved several sleep, freshness and qual-
ity‐of‐life parameters in our cohort, it is likely that signifi-
cant number of chronic BZDA users would benefit from
discontinuation. Moreover, even a reduction in BZDA use
may have positive effects on sleep. As BZDA withdrawal
improves also muscle strength and balance,7 it can be sug-
gested that risk of falls and some other adverse events
could be reduced after BZDA withdrawal.
4.3 | Strengths and limitations of the study
4.3.1 | Strengths
The present investigation is the largest follow‐up study in
the chronic BZDA users on the effects of BZDA discontin-
uation on several insomnia‐related subjective symptoms up
to 6 months after withdrawal. All participants had suffered
from primary insomnia, and for a lengthy time, nightly,
they had used zopiclone, zolpidem or temazepam as hyp-
notics, as confirmed by interviews, medical and pharmacy
records, as well as by plasma BZDA measurements.23 Of
the 92 participants, a high percentage (97%) were followed
for up to 6 months.
4.3.2 | Limitations
Firstly, our patient material was somewhat selected: individ-
uals with clear misuse of drugs or alcohol, and those with
significant psychiatric diseases were excluded. Yet, our par-
ticipants were typically older outpatient insomniacs who had
chronically used therapeutic doses of BZDAs as hypnotics.
Secondly, although baseline characteristics of partici-
pants in the Withdrawer and Nonwithdrawers groups were
rather similar, potential differences between the groups
could have influenced the results. The slightly higher age
of the Nonwithdrawers could explain their higher propor-
tion living alone and being retired. These factors might
have influenced withdrawal success, but they cannot
explain the observed effects of withdrawal on sleep‐related
parameters within the groups when the 6‐month data of the
Withdrawers or Nonwithdrawers are compared to their own
baseline data.
Thirdly, we did not use polysomnography, actigraphy or
any other objective laboratory methods for sleep measure-
ments, because we sought to discover possible changes in
perceived sleep under everyday home conditions.
4.3.3 | Conclusions
In conclusion, successful withdrawal from BZDAs can
improve perceived sleep, freshness and quality of life of
older chronic users of zopiclone, zolpidem and temazepam.
After a rebound worsening of some insomnia symptoms
during dose tapering, improvement began, with positive
effects on several sleep‐related parameters, effects signifi-
cant at 6 months after beginning of withdrawal. Some
parameters improved within 1 month. The results encour-
age a gradual BZDA withdrawal, in chronic users.
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